用免疫检查点抑制剂治疗寡进性NSCLC的放射治疗后的结果:现实世界,跨国经验.
Umair Mahmood1,2, Eleni Josephides1, Nicholas Coupe2
1Department of Oncology, Guy's and St. Thomas' NHS Foundation Trust, London SE1 9RT, UK.
Cancers
|January 10, 2026
概括
放射治疗与免疫检查点抑制剂相结合,对患有寡进性疾病的非小细胞肺癌患者显示出有前途的结果. 较高的辐射剂量和局部反应提高了生存率,指导了临床决策.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 免疫治疗是一种免疫疗法.
背景情况:
- 接受免疫检查点抑制剂 (ICI) 的非小细胞肺癌 (NSCLC) 患者的寡进性疾病 (OPD) 存在独特的管理挑战.
- 在这个特定的患者群体中评估放射治疗 (RT) 结果对于优化治疗策略至关重要.
研究的目的:
- 进行规模最大的跨国审查,评估在ICI时经历OPD的NSCLC患者的RT结果.
- 在这个队列中确定局部控制 (LC),无进展生存 (PFS) 和整体生存 (OS) 的预测因素.
主要方法:
- 在ICI (2010-2023) 期间,对103名患有OPD的NSCLC患者进行了回顾性分析,这些患者被辐射到≤5个病变.
- 统计分析包括威尔科克森试验,卡普兰-梅尔方法和单/多变量考克斯模型.
- 评估患者的人口统计,疾病特征和生存结果.
主要成果:
- 局部控制 (LC) 与中等/高辐射剂量和对RT的局部反应有关.
- 改善了无进展生存期 (PFS),与放射后的内脏OPD部位相关.
- 有利的整体存活率 (OS) 与中等/高辐射剂量,局部RT反应和OPD前ICI治疗的持续时间相关.
结论:
- 结合ICI和RT,在NSCLC的内脏OPD中显示出有希望的结果,特别是在中高剂量的辐射下.
- 在OPD之前长时间使用ICI,并实现RT的局部反应,显著提高了生存率.
- 这些发现支持多学科决策,用于管理ICI上OPD的NSCLC患者.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


